MorphoSys (MOR) Stock Price, News & Analysis

Company Overview

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Key Stats

• Today's Range: $18.96 to $18.96
• 50-Day Range: $18.96 to $18.96
• 52-Week Range: $4.18 to $19.50
• Volume: N/A
• Average Volume: 1.02 million shs
• Market Capitalization: $2.86 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.25
• Consensus Rating: Hold

MorphoSys Stock Analysis - MarketRank™

MorphoSys scored higher than 3% of companies evaluated by MarketBeat, and ranked 948th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

MorphoSys has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

MorphoSys has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MorphoSys are expected to grow in the coming year, from ($2.42) to ($1.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MorphoSys is -5.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MorphoSys is -5.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MorphoSys has a P/B Ratio of 54.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for MOR.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MorphoSys does not currently pay a dividend.

Dividend Growth

MorphoSys does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for MOR.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for MOR on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added MorphoSys to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MorphoSys insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.05% of the stock of MorphoSys is held by insiders.

Percentage Held by Institutions

Only 18.38% of the stock of MorphoSys is held by institutions.

MOR Stock Analysis - Frequently Asked Questions

How have MOR shares performed this year?

MorphoSys' stock was trading at $18.96 on January 1st, 2025. Since then, MOR stock has increased by 0.0% and is now trading at $18.96.
View the best growth stocks for 2025 here.

When did MorphoSys IPO?

MorphoSys (MOR) raised $200 million in an initial public offering (IPO) on Thursday, April 19th 2018. The company issued 8,300,000 shares at a price of $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners acted as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers.

How do I buy shares of MorphoSys?

Shares of MOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MorphoSys own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MorphoSys investors own include NVIDIA (NVDA), Broadcom (AVGO), Novo Nordisk A/S (NVO), e.l.f. Beauty (ELF), EMCOR Group (EME), Disc Medicine (IRON) and Builders FirstSource (BLDR).

Company Calendar

• Today: 2/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MOR
• CUSIP: N/A
• CIK: 1340243
• Web: www.morphosys.com
• Phone: (498) 989-9270
• Fax: 49-89-8992-7222
• Employees: 730
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $18.25
• High Stock Price Target: $18.25
• Low Stock Price Target: $18.25
• Potential Upside/Downside: -3.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-205,350,000.00
• Net Margins: -226.79%
• Pretax Margin: -225.77%
• Return on Equity: -694.31%
• Return on Assets: -22.55%

Debt

• Debt-to-Equity Ratio: 4.98
• Current Ratio: 1.38
• Quick Ratio: 1.38

Sales & Book Value

• Annual Sales: $238.28 million
• Price / Sales: 11.99
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.35 per share
• Price / Book: 54.17

Miscellaneous

• Outstanding Shares: 150,621,000
• Free Float: 150,546,000
• Market Cap: $2.86 billion
• Optionable: Not Optionable
• Beta: 1.20